Novartis' Lp(a)-lowering drug pelacarsen fails cardiovascular outcomes trial
- Novartis' pelacarsen missed the primary endpoint in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial, which enrolled 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease.
- Pelacarsen is an antisense oligonucleotide, licensed from Ionis Pharmaceuticals, designed to suppress hepatic production of Lp(a), a lipid-protein particle linked to elevated cardiovascular risk.
- The drug achieved substantial lowering of Lp(a) levels in treated patients, but this biomarker reduction did not translate into a statistically significant drop in cardiovascular death, heart attack, stroke, or urgent revascularization versus placebo.
- The result is the first major late-stage setback for the emerging Lp(a)-lowering drug class, raising questions for rival programs from Amgen and Eli Lilly that use different modalities but showed larger Lp(a) reductions in earlier-stage studies.
- Novartis and Ionis had held global rights under a licensing and collaboration deal, with Ionis having discovered and advanced pelacarsen through early development before Novartis took it into Phase 3.
Pelacarsen just became the class's first hard-outcomes readout — and it missed, despite deep Lp(a) lowering. That's the uncomfortable part: this was the cleanest test yet of the Lp(a) causal hypothesis, and it didn't confirm it. Olpasiran (Amgen) and lepodisiran (Lilly) post larger percentage reductions in early studies, but bigger knockdown of the same biomarker doesn't guarantee outcomes benefit — their own outcomes trials now carry real doubt, not just execution risk. For Novartis, this was a marquee asset licensed from Ionis to anchor its cardiovascular pipeline; the miss removes a near-term blockbuster case and puts pressure on how the Ionis partnership economics get valued going forward. Biggest read-through: Lp(a) may need rethinking as a validated drug target, not just a biomarker to chase.
Novartis' experimental cardiovascular drug fails a pivotal study ↗